Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

5.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
5.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical evaluation of a rapid polymerase chain reaction (PCR) assay: for the detection of chlamydia trachomatis in specimens from high risk patients.].

Laeknabladid·2010
Same author

[Diagnosis of chlamydia trachomatis infections in women: urinary PCR compared to cervical culture and PCR on cervical swabs in high risk females.].

Laeknabladid·2010
Same author

[Clinical evaluation of two immunoassay methods for the rapid detection of chlamydia trachomatis: antigen in endocervical specimens from high risk female patients.].

Laeknabladid·2010
Same author

[Prevalence of genital chlamydia trachomatis infections in college students.].

Laeknabladid·2010
Same author

Selective sorting of alpha-granule proteins.

Journal of thrombosis and haemostasis : JTH·2009
Same author

Mechanics of proplatelet elaboration.

Journal of thrombosis and haemostasis : JTH·2007
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Physiological Anticoagulant Deficiencies: Pathogenesis, Diagnosis, and Clinical Implications.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.7K

Road blocks in making platelets for transfusion.

J N Thon1,2,3, D A Medvetz1,2, S M Karlsson3

  • 1Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Journal of Thrombosis and Haemostasis : JTH
|July 8, 2015
PubMed
Summary
This summary is machine-generated.

Generating human platelets in the lab is crucial for future blood transfusions. This study outlines key challenges and solutions for producing lab-made platelets for clinical use.

Keywords:
biomedical engineeringbioreactorshematopoietic stem cellsmegakaryocytesplatelets

More Related Videos

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.2K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.8K

Related Experiment Videos

Last Updated: Apr 7, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.7K
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.2K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.8K

Area of Science:

  • Biotechnology
  • Hematology
  • Regenerative Medicine

Background:

  • Current platelet transfusion relies on donor availability, facing shortages.
  • Laboratory-generated platelets offer a potential solution to meet transfusion demands.

Purpose of the Study:

  • Identify and define critical roadblocks in laboratory-human platelet production.
  • Propose solutions to accelerate the clinical translation of lab-generated platelets.

Main Methods:

  • Review of current research and development in platelet bioproduction.
  • Analysis of regulatory and manufacturing challenges.
  • Identification of key technological hurdles.

Main Results:

  • Major roadblocks include scalable megakaryopoiesis, platelet yield, quality control, and regulatory pathways.
  • Proposed solutions involve advancements in bioreactor technology, cell culture media, and standardized assays.
  • Accelerated development requires interdisciplinary collaboration and streamlined regulatory strategies.

Conclusions:

  • Overcoming production challenges is essential for clinical application of lab-generated platelets.
  • Strategic implementation of proposed solutions can expedite market availability.
  • Laboratory-generated platelets hold significant promise for transfusion medicine.